Meta-analysis of randomised controlled trials with N-acetylcysteine in the treatment of schizophrenia
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Objective: There is accumulating evidence that adjunctive treatment with N-acetylcysteine may be effective for schizophrenia. This study aimed to conduct a comprehensive meta-analysis examining the efficacy of randomised control trials investigating N-acetylcysteine as an adjunct treatment for schizophrenia and the first to investigate cognition as an outcome. Methods: We systematically reviewed Medline, EmCare, PsycINFO, Embase, CINAHL Complete, China Knowledge Resource Integrated Database and the Cochrane Clinical Trials online registry for randomised control trials of N-acetylcysteine for schizophrenia. We undertook pairwise meta-analyses of N-acetylcysteine vs placebo for psychosis symptoms and cognition. Results: Seven studies, including n = 220 receiving N-acetylcysteine and n = 220 receiving placebo, met inclusion criteria for the pairwise meta-analyses. Positive and Negative Syndrome Scale negative and total scores were significantly improved in the N-acetylcysteine group after 24 weeks of treatment. The cognitive domain of working memory improved with N-acetylcysteine supplementation. Conclusion: Evidence supports the notion that N-acetylcysteine may be a useful adjunct to standard treatment for the improvement of schizophrenia symptoms, as well as the cognitive domain of working memory. Treatment effects were observed at the later time point (⩾24 weeks), suggesting that longer interventions are required for the success of N-acetylcysteine treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Keefe, R. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2003.09.011 · Cited by 1,573
Berk, M., Copolov, D., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., Judd, F., Katz, F., Katz, P., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.03.004 · Cited by 552
Self-citationBerk, M., Copolov, D. L., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., & Bush, A. I. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.022 · Cited by 500
Self-citationClinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review
Deepmala, Slattery, J., Kumar, N., Delhey, L., Berk, M., Dean, O., Spielholz, C., & Frye, R. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.04.015 · Cited by 463
Self-citationThe promise of N-acetylcysteine in neuropsychiatry
Berk, M., Malhi, G. S., Gray, L. J., & Dean, O. M. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.01.001 · Cited by 434 · cited 9×
“Evidence also suggests a link between decreased GSH concentrations and cognitive impairment (Hajjar et al., 2018; Newton et al., 2015), and it has been proposed that NAC may improve certain cognitive domains through the increased synthesis of GSH.”
BackgroundInfluentialSelf-citationGlutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients
Lavoie, S., Murray, M. M., Deppen, P., Knyazeva, M. G., Berk, M., Boulat, O., Bovet, P., Bush, A. I., Conus, P., Copolov, D., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301624 · Cited by 371
Self-citationAltered glutathione redox state in schizophrenia.
Yao, J. K., Leonard, S., & Reddy, R. (2006) · Disease Markers · doi:10.1155/2006/248387 · Cited by 321
Steullet, P., Cabungcal, J. H., Monin, A., Dwir, D., O'Donnell, P., Cuenod, M., & Do, K. Q. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2014.06.021 · Cited by 262 · cited 1×
“It has been suggested that redox dysregulation may be central to the pathophysiology of schizophrenia (Steullet et al., 2016).”
BackgroundDaglas, R., Cotton, S. M., Allott, K., Yücel, M., Macneil, C. A., Hasty, M. K., Murphy, B., Pantelis, C., Hallam, K. T., Henry, L. P., et al. (2016) · European Psychiatry · doi:10.1016/j.eurpsy.2015.09.460 · Cited by 31 · cited 1×
“In other disorders such as bipolar disorder, working memory also seems to be a domain specifically improved by pharmacotherapy (Daglas et al., 2016; Miskowiak et al., 2016).”
BackgroundSelf-citation
Cited by
The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders
Bradlow, R. C. J., Berk, M., Kalivas, P. W., Back, S. E., & Kanaan, R. A. (2022) · CNS Drugs · doi:10.1007/s40263-022-00907-3 · Cited by 87
Self-citationClinical Staging for Youth Mental Disorders: Progress in Reforming Diagnosis and Clinical Care
McGorry, P. D., & Mei, C. (2021) · Annual Review of Developmental Psychology · doi:10.1146/annurev-devpsych-050620-030405 · Cited by 38
Sarris, J., Byrne, G., Castle, D., Bousman, C., Oliver, G., Cribb, L., Blair-West, S., Brakoulias, V., Camfield, D., Ee, C., et al. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110550 · Cited by 19
“Further, as longer trial durations may be required for the potential benefits of NAC to become apparent (Yolland et al., 2020), studies with longer trial lengths are also needed.”
BackgroundSelf-citationN‐acetylcysteine for schizophrenia: A systematic review and meta‐analysis
Kishi, T., Sakuma, K., Hatano, M., & Iwata, N. (2023) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13502 · Cited by 13
“Funnel plot Table S1.”
BackgroundInfluential
Metadata
- Authors
- Yolland, C. O., Hanratty, D., Neill, E., Rossell, S. L., Berk, M., Dean, O. M., Castle, D. J., Tan, E. J., Phillipou, A., Harris, A. W., Barreiros, A. R., Hansen, A., & Siskind, D.
- Venue
- Australian & New Zealand Journal of Psychiatry
- Publisher
- SAGE Publications
- Published
- 2019-12-11
- Volume
- 54
- Issue
- 5
- Pages
- 453-466
- ISSN
- 0004-8674 (ISSN-L)
- 1440-1614
- OpenAlex
- W2996543290
- Cited by
- 107
- References
- 9
- FWCI
- 2.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Meta-analysis of randomised controlled trials with N-acetylcysteine in the treatment of schizophrenia. https://app.cochat.ai/papers/10.1177/0004867419893439
- The paper
- Yolland, C. O., Hanratty, D., Neill, E., Rossell, S. L., Berk, M., Dean, O. M., Castle, D. J., Tan, E. J., Phillipou, A., Harris, A. W., Barreiros, A. R., Hansen, A., & Siskind, D. (2020). Meta-analysis of randomised controlled trials with N-acetylcysteine in the treatment of schizophrenia. Australian & New Zealand Journal of Psychiatry. https://doi.org/10.1177/0004867419893439
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.